Prescription Patterns and Adherence to GOLD 2021 Guidelines for Chronic Obstructive Pulmonary Disease Management in Pakistan: A Cross‐Sectional Study
Verordnungsmuster und Adhärenz an die GOLD-2021-Leitlinien zur COPD-Behandlung in Pakistan: Querschnittsstudie
Health Science Reports · 2026-11 · 9 (11)
DOI: 10.1002/hsr2.73477 ↗Auf einen Blick
Bei 400 COPD-Patient:innen in Pakistan erhielten 57,0 % eine leitlinienkonforme Therapie. 43,0 % waren nicht angemessen behandelt; Über- und Untertherapie traten auf.
Fragestellung
Wie hoch sind Verordnungsmuster und Adhärenz an die GOLD-2021-Leitlinien bei Pulmonolog:innen in Pakistan, und welche Faktoren sind mit Abweichungen verbunden?
Methode
Querschnittsbeobachtungsstudie in sekundären Versorgungseinrichtungen in Rawalpindi und Islamabad; April bis September 2022. COPD wurde per Spirometrie bestätigt und nach GOLD 2021 ABCD eingeteilt.
Ergebnisse
400 Patient:innen, mittleres Alter 61,8 ± 10,0 Jahre, 74,8 % männlich. Leitlinienkonform: 57,0 % (228/400; 95 %-KI 52,1–61,9 %). Nicht angemessen: 43,0 % (172/400; 95 %-KI 38,1–47,9 %).
Schlussfolgerung der Autor:innen
Mehr als zwei Fünftel der Patient:innen erhielten eine nicht mit GOLD 2021 übereinstimmende Pharmakotherapie. Es wurden Über- und Untertherapie beobachtet.
Kernaussagen
- 57,0 % erhielten eine leitlinienkonforme Therapie
- 43,0 % wurden nicht angemessen behandelt
- Kardiovaskuläre Komorbidität und männliches Geschlecht waren mit Abweichungen assoziiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Leitlinie in der Zeitschrift Health Science Reports, online erschienen am 10.11.2026. Verfasst von Hafsa Kanwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Quaid-i-Azam University Islamabad Pakistan. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Higher Education Commission, Pakistan.
Themen: COPD
Abstract (Originalsprache)
Background and Aims Global Initiative for chronic obstructive lung disease (GOLD) offers evidence‐based recommendations for the management of COPD, but compliance with the guidelines amongst physicians in LMC countries is varied. The objective of this study was to determine the prescribing pattern of inhaled COPD medications in Pakistan and to evaluate the adherence of pulmonologists with the GOLD 2021 guidelines and to assess all the factors that would affect the adherence.
Methods
This cross‐sectional observational study was undertaken at secondary health care facilities Rawalpindi and Islamabad between the period of April–September, 2022. Spirometry, COPD Assessment Test (CAT) and Modified Medical Research Council (mMRC) scores were used to classify outpatients ≥ 40 years old who had COPD confirmed by spirometry into GOLD 2021 ABCD groups. Pharmacological regimens recommended by GOLD were compared with prescribed regimens. Adherence was rated as appropriate, overtreatment or undertreatment. Demographic and clinical variables were correlated with adherence using chi‐square and t‐test.
Results
Among 400 patients (mean age 61.8 ± 10.0 years; 74.8% male), Group B was most frequent (40.3%), followed by C (24.0%), A (23.8%), and D (12.0%). Overall, 57.0% (228/400; 95% CI: 52.1–61.9%) received guideline‐concordant therapy, while 43.0% (172/400; 95% CI: 38.1–47.9%) were inappropriately managed. The 80 patients were considered to be overtreated and 92 patients were considered to be undertreated among the inappropriate prescriptions. Cardiovascular comorbidity was associated with treatment inappropriateness (OR, 1.57; 95% CI, 1.05–2.34; p = 0.026), and male sex was also significantly associated with inappropriate prescribing (OR, 2.36; 95% CI, 1.44–3.85; p = 0.001).
Conclusion
More than two‐fifths of patients received pharmacological treatment that was not concordant with GOLD 2021 recommendations. Both overtreatment and undertreatment were observed. Strengthening spirometry‐based assessment, clinician education, and access to appropriate inhaled therapies may improve guideline‐concordant COPD management in Pakistan.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Quaid-i-Azam University Islamabad Pakistan.
- Department of Clinical Pharmacy and Pharmacology, Rak College of Pharmacy RAK Medical and Health Sciences University Ras Al Khaimah United Arab Emirates.
- Department of Pharmacy The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China.
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy Health Science Center Xi'an Jiaotong University Xi'an China.
- Department of Pharmaceutical Sciences Pak-Austria Fachhochshule: Institute of Applied Haripur Pakistan.
- Department of Statistics Government College Women University Sialkot Pakistan.
ORCID-Profile: Syed Sikandar Shah, Areeg Anwer Ali, Amjad Khan, Saima Mushtaq, Mahwish Rabia
Förderung
- Higher Education Commission, Pakistan
Zitieren
APA
Kanwal, H., Shah, S. S., Ali, A. A., Khan, A., Umm-E-Kalsoom, Mushtaq, S., Rabia, M., & Fang, Y. (2026). Prescription Patterns and Adherence to GOLD 2021 Guidelines for Chronic Obstructive Pulmonary Disease Management in Pakistan: A Cross‐Sectional Study. Health Science Reports, 9(11). https://doi.org/10.1002/hsr2.73477
Vancouver
Kanwal H, Shah SS, Ali AA, Khan A, Umm-E-Kalsoom, Mushtaq S, et al. Prescription Patterns and Adherence to GOLD 2021 Guidelines for Chronic Obstructive Pulmonary Disease Management in Pakistan: A Cross‐Sectional Study. Health Science Reports. 2026;9(11). doi:10.1002/hsr2.73477
BibTeX
@article{Kanwal2026,
author = {Kanwal, Hafsa and Shah, Syed Sikandar and Ali, Areeg Anwer and Khan, Amjad and Umm-E-Kalsoom and Mushtaq, Saima and Rabia, Mahwish and Fang, Yu},
title = {Prescription Patterns and Adherence to GOLD 2021 Guidelines for Chronic Obstructive Pulmonary Disease Management in Pakistan: A Cross‐Sectional Study},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/hsr2.73477}
}
EUVIMED